A new Sanofi (Euronext: SAN) survey has found that only 6% of cardiologists are currently prescribing PCSK9 blockers, while 97% say they are satisfied with outcomes from these treatments.
PCSK9 inhibitors lower LDL cholesterol levels and are used to treat primary hypercholesterolemia and mixed lipidemia.
Several years after launch, neither Sanofi’s Praluent (alirocumab), developed with Regeneron Pharmaceuticals (Nasdaq: REGN), nor Amgen’s (Nasdaq: AMGN) Repatha (evolocumab), have had the level of market impact that analysts had expected.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze